Assesses whether a patient performs self-monitoring blood glucose (SMBG) fingerstick calibrations as required for their real-time CGM system. Triggers include: 'Verify patient performs fingerstick calibrations', 'Ensure calibration schedule is followed'.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
The skill suggests using real-time continuous glucose monitoring (CGM) combined with algorithm-driven insulin pumps (ADIPs) rather than multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG) three or more times daily for adults and children with type 1 diabetes (T1D) to lower hypoglycemia incidence. Clinical triggers include discussions about insulin pump therapy, CGM use, or reducing hypoglycemia in T1D patients on intensive insulin regimens.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
This skill recommends using radiation therapy for corticotroph adenomas in Cushing's disease when imaging shows invasive features or mass‑effect concerns such as cavernous sinus invasion, suprasellar extension, or knobby protrusion. Consider RT when postoperative medical therapy has normalized cortisol but tumor progression or residual invasive disease is suspected.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
This skill recommends obtaining a postoperative pituitary MRI within 1–3 months after successful transsphenoidal surgery (TSS) to establish a new baseline for future recurrence assessment. Use when a Cushing’s syndrome patient has achieved biochemical remission post‑TSS and is entering routine follow‑up.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
This skill provides a shared decision-making framework for selecting second-line therapies in patients with ACTH-dependent Cushing's syndrome who have persistent hypercortisolism after transsphenoidal surgery or for whom surgery is not feasible. Clinical triggers include "failed TSS", "non-curative pituitary surgery", "persistent UFC elevation post-op", and "surgery contraindicated".
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
This skill recommends transsphenoidal selective adenomectomy (TSS) by an experienced pituitary surgeon as the optimal treatment for Cushing's disease in pediatric and adult patients. Use when a patient with ACTH-dependent Cushing syndrome is a surgical candidate; triggers include overt Cushing's syndrome, elevated UFC or late-night salivary cortisol, and pituitary MRI showing an adenoma.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Selects spironolactone as first-line mineralocorticoid receptor antagonist for bilateral primary aldosteronism, with eplerenone as an alternative when spironolactone–related adverse effects are problematic. Trigger phrases include 'confirmed bilateral PA on AVS', 'idiopathic adrenal hyperplasia', 'bilateral adrenal hyperplasia', 'glucocorticoid-remediable aldosteronism', and 'initiating medical therapy for bilateral adrenal disease'.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Recommends ACTH stimulation during AVS to improve success rate of bilateral selective catheterization, acknowledging unclear impact on diagnostic accuracy for laterality. Triggers include when setting up AVS and asking 'Should I administer ACTH?' or considering procedural optimization.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Determines successful catheterization in adrenal venous sampling by applying selectivity index cut‑offs with and without ACTH stimulation. Triggered during AVS when measuring cortisol levels and asking “Is the catheter properly positioned?” or when reviewing results for technical adequacy.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Recommends checking and managing vitamin D according to Endocrine Society guidelines to avoid hypocalcemia in patients receiving bisphosphonates or denosumab for hypercalcemia of malignancy. Use when a clinician notes risk factors for hypocalcemia (e.g., low 25‑OH vitamin D, renal insufficiency) and asks about baseline labs before antiresorptive start.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Identifies patients with a positive aldosterone-to-renin ratio screening who may proceed directly to subtype testing without confirmatory testing based on specific clinical criteria. Triggers include spontaneous hypokalemia, baseline plasma aldosterone concentration >100 pg/mL (CLEIA), renin suppression, or a clinician questioning the need for a confirmatory test after a positive screen.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Determines whether to recommend adrenalectomy or mineralocorticoid receptor antagonists for primary aldosteronism based on PA subtype and patient/surgical factors. Triggered after subtype confirmation when clinicians ask “Should this patient have surgery or medical treatment?” or discuss treatment options with the patient.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
This skill suggests using denosumab rather than an intravenous bisphosphonate for adults with hypercalcemia of malignancy. It is triggered when a clinician questions which antiresorptive to choose first or seeks guidance on drug selection for HCM.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Selects the aldosterone-to-renin ratio (ARR) method over hypokalemia for screening hypertensive patients for primary aldosteronism. Use when a clinician asks what test to use for screening hypertensive patients with resistant hypertension or unexplained hypokalemia for PA.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Recommends equipping every patient with primary adrenal insufficiency (PAI) with a glucocorticoid injection kit for emergency self‑administration and providing training on its use. Trigger when preparing a PAI patient for stress dosing, adrenal crisis prevention, or when prescribing glucocorticoid replacement and needing to ensure emergency preparedness.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Suggests using longer-acting glucocorticoids when standard hydrocortisone regimens are impractical due to nonavailability, poor adherence, or need for once-daily dosing. Triggers include glucocorticoid replacement therapy decisions where patients report difficulty with multiple daily doses, lack of access to hydrocortisone, or preference for simplified regimens.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Suggests avoiding synthetic, long-acting glucocorticoids (e.g., prednisolone, dexamethasone) in children with primary adrenal insufficiency (PAI). Use when selecting glucocorticoid replacement for a child with PAI to prevent Cushingoid side effects and dose titration difficulties.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Complete bedside prescribing reference for Mirago (mirabegron, beta-3 adrenoceptor agonist) for overactive bladder — covering contraindications, safety screening, drug interactions, dose selection in special populations, titration, and administration. Use when a clinician asks how to start mirabegron, what dose to use in renal or hepatic impairment, is mirabegron safe in this patient, mirabegron drug interactions, or Mirago for OAB.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Recommends against dexamethasone for glucocorticoid replacement in primary adrenal insufficiency (PAI) due to risk of Cushingoid side effects from difficult dose titration. Use when selecting a glucocorticoid for PAI management to avoid iatrogenic Cushing syndrome.
日本語の概要は準備中です。原文の説明を表示しています。
dromlakhani/MD2SKILL☆ 142026年10月5日 更新
Standard operating procedure for producing a documentation page end to end — gather source material, classify, draft against the measured corpus profile, then run the reader-level and humanizer passes and both gates. Use for any page on a documentation surface, or when rewriting a page that reads as machine-written. Orchestrates technical-writing, reader-level and humanizer in a fixed order.
日本語の概要は準備中です。原文の説明を表示しています。
friedbotstudio/baseline☆ 142026年10月13日 更新
Contract document for the binding test verdict file at .claude/state/last_test_result. Format spec for callers (integrate, simplify, chore, the verify-tick worker) that inline the four mechanical operations. Not Skill-tool-invocable.
日本語の概要は準備中です。原文の説明を表示しています。
friedbotstudio/baseline☆ 142026年10月13日 更新
Execute a swarm plan wave by wave with filesystem isolation via git worktrees. For each wave, main context decides the scenario recipe + implementation contract for every task, then spawns one swarm-worker per task in parallel. Each worker executes its recipe and reports JSON status. Worktree merge-audit verifies write-set discipline before changes land on main. Aborts remaining waves on any audit or task failure.
日本語の概要は準備中です。原文の説明を表示しています。
friedbotstudio/baseline☆ 142026年10月13日 更新
Decompose an approved spec into a dependency-ordered swarm plan — one task per component, each with an explicit write_set. Produces `.claude/state/swarm/<slug>.json` with tasks + waves. The wave scheduler guarantees pairwise-disjoint write_sets within each wave so parallel dispatch is provably conflict-free.
日本語の概要は準備中です。原文の説明を表示しています。
friedbotstudio/baseline☆ 142026年10月13日 更新